TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31055857

Group type: EXPERIMENTAL
Intervention: Whey protein (1 g/kg body weight)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Glucose (1 g/kg body weight)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Calorie-free control
Number of subjects: 23
Study: 29325236

Group type: EXPERIMENTAL
Intervention: relamorelin 100 μg subcutaneously daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 27498268

Group type: EXPERIMENTAL
Intervention: McGrath MAC videolaryngoscope
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 86
Study: 25154378

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 218
Study: 23724879

Group type: EXPERIMENTAL
Intervention: 5 mg·kg(‐1)·day(‐1) of caffeine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (malt-dextrin)
Number of subjects: 30
Study: 20835904

Group type: EXPERIMENTAL
Intervention: Acute exercise session (50-min on cycle-ergometer at 65% peak oxygen uptake)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Chronic exercise program (4 months)
Number of subjects: 34
Study: 18311749

Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone therapy (PHT)
Number of subjects: 27347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27347
Study: 17156486

Group type: EXPERIMENTAL
Intervention: Oculomotor capture task with irrelevant stimulus
Number of subjects: 23
Study: 12681528

Group type: EXPERIMENTAL
Intervention: GHB (50 mg/kg t.i.d for 3 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: NTX (50 mg/day for 3 months)
Number of subjects: 35
Study: 10669272

Group type: COMPARATOR
Intervention: Ropivacaine 0.75% plus NaCL 0.9% (Group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% plus 0.150 mg clonidine (Group II)
Number of subjects: 0
Study: 9074543

Group type: EXPERIMENTAL
Intervention: MAG3 SPECT with a graduated dose of 20 mCi (minimum 2 mCi) of 99mTc‐MAG3
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MAG3 SPECT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Simultaneous injection of MAG3 and a diuretic (2-40 mg furosemide)
Number of subjects: 10
Study: 8364134

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine nocte
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine b.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine q.d.s.
Number of subjects: 0
Study: 3714083

Group type: EXPERIMENTAL
Intervention: Thyropramide (300 mg per diem for 3 days per os)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29804023

Group type: EXPERIMENTAL
Intervention: Personalised exercise programme (12-week programme focusing on strength, balance, flexibility, and walking endurance)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Personalised exercise programme
Number of subjects: 15
Study: 26778744

Group type: EXPERIMENTAL
Intervention: Preoperative warm up training using a virtual reality simulator
Number of subjects: 10

Group type: COMPARATOR
Intervention: No warm up before surgery
Number of subjects: 10
Study: 24942975

Group type: EXPERIMENTAL
Intervention: High beta-palmitate formula (HBP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low beta-palmitate formula (LBP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Breastfeeding (BF)
Number of subjects: 63
Study: 23275364

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (4 g/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 21986122

Group type: EXPERIMENTAL
Intervention: Ulinastatin (5000 U/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 0
Study: 18201206

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 mg + Glimepiride (GLIM) 3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 8 mg + Glimepiride (GLIM) 3 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO) + Glimepiride (GLIM) 3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 mg + Glimepiride (GLIM) (low-dose prior to uptitration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride (GLIM) monotherapy
Number of subjects: 0
Study: 16516304

Group type: EXPERIMENTAL
Intervention: SSRI treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12716264

Group type: EXPERIMENTAL
Intervention: Gepirone-ER (20-80 mg/day)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 11584879

Group type: EXPERIMENTAL
Intervention: Distraction condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-distraction condition
Number of subjects: 0
Study: 9196146

Group type: EXPERIMENTAL
Intervention: Truquant BR radioimmunoassay (RIA) for CA 27.29 antigen
Number of subjects: 166
Study: 1589233

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: No choice
Number of subjects: 20
Study: 3091627

Group type: EXPERIMENTAL
Intervention: 2.5 ng/kg X min GHRH
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 15 ng/kg X min GHRH
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.15 M NaCl (Control)
Number of subjects: 6
Study: 29656488

Group type: EXPERIMENTAL
Intervention: Nutrition-focused MNCH (intensified interpersonal counselling, community mobilization, distribution of free micronutrient supplements, and weight-gain monitoring)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard MNCH (antenatal care with standard nutrition counselling)
Number of subjects: 0
Study: 26756540

Group type: EXPERIMENTAL
Intervention: Passive intervertebral neck manipulation and neck range of motion exercises
Number of subjects: 22

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 22
Study: 23980743

Group type: EXPERIMENTAL
Intervention: Low-temperature atmospheric pressure plasma (LTAPP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 2.5% NaOCl (positive control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Gaseous ozone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 42
Study: 22402418

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-20mg/day) started within 12 hours after admission for two weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-20mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atorvastatin group
Number of subjects: 50
Study: 20445152

Group type: EXPERIMENTAL
Intervention: Dual-task-based exercise training
Number of subjects: 61

Group type: COMPARATOR
Intervention: Unspecific low-intensity exercise (Control Group)
Number of subjects: 61
Study: 18331218

Group type: EXPERIMENTAL
Intervention: Acute normobaric hypoxia (Hy; n = 10)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normoxia (Con; n = 7)
Number of subjects: 17
Study: 20553655

Group type: EXPERIMENTAL
Intervention: SUD patients who died by suicide (n = 854)
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Concurrent psychopathology in SUD patients who died by suicide (n = 854)
Number of subjects: 854
Study: 16356186

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (3 individual sessions and 1 group session)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study: 11487258

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg o.d.)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg o.d.)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Anastrozole and Tamoxifen (1 mg and 20 mg o.d. respectively)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 347

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Anastrozole and Tamoxifen
Number of subjects: 347
Study: 9740099

Group type: EXPERIMENTAL
Intervention: Bimanual motor activation task
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) administration
Number of subjects: 6
Study: 8310485

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin 12,000 IU (Group 2)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin 24,000 IU (Group 3)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (Group 1)
Number of subjects: 114
Study: 3140862

Group type: EXPERIMENTAL
Intervention: nalmefene 0.4 mg/70 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: naloxone 0.4 mg/70 kg (low dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: naloxone 1.6 mg/70 kg (high dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 0
Study: 31111682

Group type: EXPERIMENTAL
Intervention: Propensity score methods for covariate adjustment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional regression approach
Number of subjects: 0
Study: 30157896

Group type: EXPERIMENTAL
Intervention: 3 monthly ART supply through community ART groups (CAGs)
Number of subjects: 5760

Group type: EXPERIMENTAL
Intervention: 6 monthly ART supply through community ART distribution points (CAD)
Number of subjects: 5760

Group type: COMPARATOR
Intervention: 3 monthly ART supply at facilities
Number of subjects: 5760
Study: 26895633

Group type: EXPERIMENTAL
Intervention: GTR and PDLSC sheets in combination with Bio‐oss(®) (Cell group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: GTR and Bio‐oss(®) without stem cells (Control group)
Number of subjects: 30
Study: 24013470

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted TME with ASP
Number of subjects: 80

Group type: COMPARATOR
Intervention: Open TME with ASP
Number of subjects: 80
Study: 22785264

Group type: EXPERIMENTAL
Intervention: SB-PACT (School-Based Preventive Asthma Care Technology)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 20618595

Group type: EXPERIMENTAL
Intervention: Stretching exercise (daily from 18 weeks of gestation to the end of pregnancy)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Walking exercise (daily from 18 weeks of gestation to the end of pregnancy)
Number of subjects: 124
Study: 17485435

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 38

Group type: COMPARATOR
Intervention: Desflurane anaesthesia
Number of subjects: 38
Study: 15942292

Group type: EXPERIMENTAL
Intervention: B7 gene polymorphisms (CD80 and CD86)
Number of subjects: 146
Study: 11795727

Group type: EXPERIMENTAL
Intervention: 25 N tension during fixation
Number of subjects: 50

Group type: COMPARATOR
Intervention: 50 N tension during fixation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 10696686

Group type: EXPERIMENTAL
Intervention: Clopidogrel (Plavix)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticlopidine (Ticlid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 7673544

Group type: EXPERIMENTAL
Intervention: Active nicotine patches
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 34
Study: 2209306

Group type: EXPERIMENTAL
Intervention: Graduated tuning fork
Number of subjects: 189
Study: 7468948

Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline sulphate aerosol via a 10 cm tube extension
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.2 mg salbutamol sulphate via conventional pressurized aerosol
Number of subjects: 32
Study: 31242534

Group type: EXPERIMENTAL
Intervention: Conjunctive estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disjunctive estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint event probabilities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjunctive-less likely probability difference
Number of subjects: 0
Study: 27000391

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 135

Group type: COMPARATOR
Intervention: Non-edoxaban (control group)
Number of subjects: 135
Study: 25989606

Group type: EXPERIMENTAL
Intervention: 5 mg/day memantine (MMT+M)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo (MMT+P)
Number of subjects: 134
Study: 24604528

Group type: EXPERIMENTAL
Intervention: Fit2Quit intervention (10 exercise telephone counseling sessions over 6 months) plus usual care (behavioral counseling and nicotine replacement therapy)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 906
Study: 21121983

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg/day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 18950932

Group type: EXPERIMENTAL
Intervention: HIFU ablation of primary breast cancer, followed by modified radical mastectomy within 1-2 weeks.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Modified radical mastectomy (control group).
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: HIFU group (compared to control group).
Number of subjects: 48
Study: 17335331

Group type: EXPERIMENTAL
Intervention: TEAM study (RCT)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Phenomenology study
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 247
Study: 15303246

Group type: EXPERIMENTAL
Intervention: 3 units of alcohol consumed >90 min previously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nil alcohol
Number of subjects: 20
Study: 12375667

Group type: EXPERIMENTAL
Intervention: G-CSF (3 microg/kg) plus dexamethasone (8 mg orally)
Number of subjects: 52

Group type: COMPARATOR
Intervention: G-CSF (12 microg/kg) alone
Number of subjects: 52
Study: 10530096

Group type: EXPERIMENTAL
Intervention: Braun Oral-B 3D Plaque Remover
Number of subjects: 35

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 35
Study: 8090844

Group type: EXPERIMENTAL
Intervention: Intense endurance exercise training for 12 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 11
Study: 2574842

Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon) therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 780403

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Papase
Number of subjects: 0
Study: 31647125

Group type: COMPARATOR
Intervention: Attention control group activities
Number of subjects: 148

Group type: COMPARATOR
Intervention: Conversation (20.1% of visit time)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Playing games (18.7% of visit time)
Number of subjects: 148
Study: 29208786

Group type: EXPERIMENTAL
Intervention: Short implants
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional implants
Number of subjects: 10
Study: 25479585

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate 20 mg in 500 mL of 5% glucose solution
Number of subjects: 818

Group type: COMPARATOR
Intervention: Control group (500 mL of 5% glucose solution)
Number of subjects: 818
Study: 22883321

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) combined with fat graft
Number of subjects: 25

Group type: COMPARATOR
Intervention: Platelet-rich fibrin (PRF) combined with fat graft
Number of subjects: 25
Study: 21600518

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 134
Study: 17976942

Group type: EXPERIMENTAL
Intervention: Scirrhous HCC
Number of subjects: 317

Group type: COMPARATOR
Intervention: Usual HCC
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Both groups after curative resection
Number of subjects: 317
Study: 17908726

Group type: EXPERIMENTAL
Intervention: Healthy Buddies program (2‐3 hours/week for 21 weeks)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 383
Study: 15476624

Group type: EXPERIMENTAL
Intervention: Abciximab-coated stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stents
Number of subjects: 0
Study: 11721808

Group type: EXPERIMENTAL
Intervention: MR urography with contrast medium administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MR renograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contrast medium administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual determination of hydronephrosis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual determination of unilateral delayed excretion of contrast material
Number of subjects: 20
Study: 9805722

Group type: EXPERIMENTAL
Intervention: New antenatal care (ANC) programme consisting of tests, clinical procedures, and follow-up actions
Number of subjects: 24000

Group type: COMPARATOR
Intervention: Traditional programme currently in use (control group)
Number of subjects: 24000

Group type: EXPERIMENTAL
Intervention: New antenatal care (ANC) programme
Number of subjects: 24000
Study: 8728911

Group type: EXPERIMENTAL
Intervention: 10mg diazepam administered intravenously
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no diazepam)
Number of subjects: 60
Study: 2654259

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg daily (N = 37)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (N = 33)
Number of subjects: 70
Study: 799565

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Trial workload
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Psychological effects
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Cost of full-scale trial
Number of subjects: 18000
Study: 31712768

Group type: EXPERIMENTAL
Intervention: spring milk fat
Number of subjects: 172

Group type: COMPARATOR
Intervention: vegetable fat
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: winter milk fat
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: winter milk fat supplemented with calcium
Number of subjects: 172
Study: 31229734

Group type: EXPERIMENTAL
Intervention: Face-to-face communication partner training
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Telepractice communication partner training
Number of subjects: 55
Study: 27056549

Group type: EXPERIMENTAL
Intervention: Integrated care and participatory workplace intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 25488124

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2.0 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (22 age- and sex-matched healthy patients)
Number of subjects: 38
Study: 22730366

Group type: EXPERIMENTAL
Intervention: secukinumab 25 mg, 75 mg, 150 mg, 300 mg
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: secukinumab 75 mg, 150 mg, 300 mg
Number of subjects: 237

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 237
Study: 21255083

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 2507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2507
Study: 19953901

Group type: EXPERIMENTAL
Intervention: Drainage
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Drainage
Number of subjects: 30
Study: 16501017

Group type: EXPERIMENTAL
Intervention: Endurance training (5 sessions/week for 2 weeks at 70-80% of maximal HR)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Baseline and post-endurance training
Number of subjects: 95
Study: 15053124

Group type: EXPERIMENTAL
Intervention: Outreach nurse support consisting of three telephone contacts and one home visit within six months after discharge.
Number of subjects: 173
Study: 15489091

Group type: EXPERIMENTAL
Intervention: Renal insufficiency categorized as creatinine clearance (CrCl) 40 to 60 ml/min
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Renal insufficiency categorized as creatinine clearance (CrCl) <40 ml/min
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (users)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (nonusers)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Renal insufficiency
Number of subjects: 702
Study: 10699806

Group type: EXPERIMENTAL
Intervention: Endolymphatic shunt procedure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9120174

Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 95

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 95
Study: 8227798

Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg twice daily (n = 20)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 32
Study: 2876723

Group type: EXPERIMENTAL
Intervention: 0.2 mg levocabastine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 8 mg disodium cromoglycate (DSCG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2786751

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody 260F9‐recombinant ricin A chain (10 micrograms/kg daily)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody 260F9‐recombinant ricin A chain (50 micrograms/kg daily)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody 260F9‐recombinant ricin A chain (10 micrograms/kg and 50 micrograms/kg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody 260F9‐recombinant ricin A chain (50 micrograms/kg)
Number of subjects: 4
Study: 31050956

Group type: EXPERIMENTAL
Intervention: Light therapy (Bioptron)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (exercises and cryotherapy)
Number of subjects: 52
Study: 28914415

Group type: EXPERIMENTAL
Intervention: Warfarin loading doses (1.5 times the maintenance dose for 3 days followed by pre‐procedural warfarin maintenance dosing)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Warfarin maintenance doses
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Warfarin loading doses
Number of subjects: 39